BRCA2 and ovarian carcinoma: While secondary mutations antagonizing a primary mutation in BRCA2 through excision of the mutated area has been shown to revert platinum drug sensitivity in breast as well as ovarian carcinomas [30, 31], to the best of our knowledge, secondary SNP's antagonizing the effect of a previous SNP on the same gene, have not previously been reported (Figure 3).